Released May 3, 2023, after the close
10-Q filed May 3, 2023, 33 days after period end · 0000950170-23-017175
Q1 2023 · 10-Q
Revenue$58.98M$58.98M +220.3% vs Q1 2022+33.0% vs Q4 2022
Net Income-$18.88M-$18.88M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.19-$0.19 N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$28,592,000N/M
Operating Cash Flow-$28,860,000N/M
Free Cash Flowderived-$32,068,000N/M
Margins · derived
Operating margin-48.5%+355.9 pt vs Q1 2022
Net margin-32.0%+324.7 pt vs Q1 2022
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $58.98M | $18.41M | $11.14M | $2.52M |
| Net Income | -$18.88M | -$65.69M | -$45.09M | -$33.52M |
| EPS Diluted | -$0.19 | -$0.68 | -$0.48 | -$0.44 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR